Lois Witters

811 total citations
19 papers, 668 citations indexed

About

Lois Witters is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Lois Witters has authored 19 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Molecular Biology. Recurrent topics in Lois Witters's work include HER2/EGFR in Cancer Research (10 papers), Bone health and treatments (4 papers) and Cancer Treatment and Pharmacology (4 papers). Lois Witters is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), Bone health and treatments (4 papers) and Cancer Treatment and Pharmacology (4 papers). Lois Witters collaborates with scholars based in United States, India and Canada. Lois Witters's co-authors include Allan Lipton, Vernon M. Chinchilli, Linda Engle, Rakesh Kumar, Suhail M. Ali, Allan Lipton, Harold A. Harvey, Pirow Bekker, Kim Leitzel and Steven Friedman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Chemistry.

In The Last Decade

Lois Witters

19 papers receiving 647 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lois Witters United States 11 500 262 146 110 100 19 668
Jacqueline Akech United States 13 326 0.7× 600 2.3× 30 0.2× 302 2.7× 133 1.3× 14 825
Allen Saliganan United States 12 275 0.6× 263 1.0× 38 0.3× 181 1.6× 202 2.0× 14 605
Leonor Wenger United States 12 236 0.5× 432 1.6× 13 0.1× 151 1.4× 32 0.3× 15 714
Qunling Zhang China 15 390 0.8× 482 1.8× 93 0.6× 189 1.7× 226 2.3× 51 972
Julienne Gladu Canada 8 235 0.5× 268 1.0× 22 0.2× 128 1.2× 96 1.0× 10 459
M. Katie Conley‐LaComb United States 9 204 0.4× 245 0.9× 30 0.2× 134 1.2× 179 1.8× 9 507
Guoxian Long China 15 291 0.6× 289 1.1× 45 0.3× 217 2.0× 108 1.1× 35 661
Jia-Han Ding China 8 277 0.6× 484 1.8× 35 0.2× 402 3.7× 396 4.0× 14 905
Simone Bonardi Italy 11 403 0.8× 352 1.3× 38 0.3× 426 3.9× 85 0.8× 13 769
CL Arteaga United States 12 544 1.1× 429 1.6× 139 1.0× 175 1.6× 316 3.2× 27 946

Countries citing papers authored by Lois Witters

Since Specialization
Citations

This map shows the geographic impact of Lois Witters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lois Witters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lois Witters more than expected).

Fields of papers citing papers by Lois Witters

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lois Witters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lois Witters. The network helps show where Lois Witters may publish in the future.

Co-authorship network of co-authors of Lois Witters

This figure shows the co-authorship network connecting the top 25 collaborators of Lois Witters. A scholar is included among the top collaborators of Lois Witters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lois Witters. Lois Witters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Lipton, Allan, et al.. (2010). Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer. Journal of Clinical Gastroenterology. 44(4). 286–288. 60 indexed citations
2.
Lipton, Allan, Lois Witters, & Hanspeter Nick. (2009). Growth Inhibition of Human Breast Cancer Cells with an Iron Chelator (Deferasirox) and Docetaxel.. Cancer Research. 69(24_Supplement). 5075–5075. 1 indexed citations
3.
Witters, Lois, Peggy Scherle, Steven Friedman, et al.. (2008). Synergistic Inhibition with a Dual Epidermal Growth Factor Receptor/HER-2/neu Tyrosine Kinase Inhibitor and a Disintegrin and Metalloprotease Inhibitor. Cancer Research. 68(17). 7083–7089. 87 indexed citations
4.
Witters, Lois, et al.. (2007). Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncology Reports. 17(2). 465–9. 43 indexed citations
5.
Witters, Lois, et al.. (2006). Synergistic inhibition of breast cancer cell lines with the combination of a dual inhibitor of EGFR/HER-2/neu and a Bcl-2 inhibitor. Journal of Clinical Oncology. 24(18_suppl). 13100–13100. 1 indexed citations
6.
Kerr, Stephen J., et al.. (2005). Phase II trial of gemcitabine and irinotecan plus celecoxib in advanced adenocarcinoma of the pancreas. Journal of Clinical Oncology. 23(16_suppl). 4155–4155. 8 indexed citations
7.
Witters, Lois, et al.. (2004). Combining flavopiridol with various signal transduction inhibitors. Oncology Reports. 11(3). 693–8. 5 indexed citations
8.
Lipton, Allan, et al.. (2004). Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.. PubMed. 18(14 Suppl 14). 43–5. 9 indexed citations
9.
Witters, Lois, et al.. (2003). Effect of the Combination of Docetaxel, Zoledronic Acid, and a COX-2 Inhibitor on the Growth of Human Breast Cancer Cell Lines. American Journal of Clinical Oncology. 26(Supplement 2). S92–S97. 38 indexed citations
10.
Witters, Lois, et al.. (2003). Decreased Response to Paclitaxel Versus Docetaxel in HER-2/neu Transfected Human Breast Cancer Cells. American Journal of Clinical Oncology. 26(1). 50–54. 36 indexed citations
11.
Witters, Lois, Linda Engle, & Allan Lipton. (2002). Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncology Reports. 9(6). 1163–6. 41 indexed citations
12.
Lipton, Allan, Suhail M. Ali, Kim Leitzel, et al.. (2002). Serum osteoprotegerin levels in healthy controls and cancer patients.. PubMed. 8(7). 2306–10. 108 indexed citations
13.
Witters, Lois, et al.. (2001). Inhibition of growth of human breast cancer cell lines with the combination of zoledronic acid and a COX-2 inhibitor. European Journal of Cancer. 37. S78–S78. 3 indexed citations
14.
Witters, Lois, Rakesh Kumar, Mahitosh Mandal, et al.. (1999). Antisense oligonucleotides to the epidermal growth factor receptor. Breast Cancer Research and Treatment. 53(1). 41–50. 31 indexed citations
15.
Witters, Lois, Rakesh Kumar, Vernon M. Chinchilli, & Allan Lipton. (1997). Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Research and Treatment. 42(1). 1–5. 78 indexed citations
16.
KOPRESKI, MICHAEL S., Lois Witters, William A. Brennan, et al.. (1996). Protein tyrosine kinase activity in breast cancer and its relation to prognostic indicators.. PubMed. 16(5B). 3037–41. 9 indexed citations
17.
Witters, Lois, et al.. (1995). Epidermal growth factor receptor ectodomain in the urine of patients with squamous cell carcinoma.. PubMed. 1(5). 551–7. 10 indexed citations
18.
Lipton, Allan, Laurence M. Demers, Christopher Hamilton, et al.. (1993). Increased urinary excretion of pyridinium cross-links in cancer patients.. PubMed. 39(4). 614–8. 53 indexed citations
19.
Lipton, Allan, Laurence M. Demers, Christopher Hamilton, et al.. (1993). Increased urinary excretion of pyridinium cross-links in cancer patients. Clinical Chemistry. 39(4). 614–618. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacqueline Akech Breakdown of academic impact, for papers by Allen Saliganan Breakdown of academic impact, for papers by Leonor Wenger Breakdown of academic impact, for papers by Qunling Zhang Breakdown of academic impact, for papers by Julienne Gladu Breakdown of academic impact, for papers by M. Katie Conley‐LaComb Breakdown of academic impact, for papers by Guoxian Long Breakdown of academic impact, for papers by Jia-Han Ding Breakdown of academic impact, for papers by Simone Bonardi Breakdown of academic impact, for papers by CL Arteaga
Rankless by CCL
2026